Clinical Trial Update: Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction [Phase 2]

View source ↗

Summary

Clinical trial evaluates the safety and efficacy of combining ibrutinib with daratumumab in relapsed/refractory chronic lymphocytic leukemia with p53 dysfunctio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• DARZALEX (daratumumab)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING